Featured
New Treatment for Uveal Melanoma: HEPZATO
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) from Worldwide Markets

Pfizer announced on September 25, 2024, that they are voluntarily withdrawing all lots of OXBRYTA (voxelotor) and discontinuing all active clinical trials and expanded access programs worldwide.

FDA Approves Tecelra, First T Cell Therapy for Solid Tumors